Director Gilla Kaplan of Tyra Biosciences, Inc. (NASDAQ: TYRA) moved to monetize a portion of an equity position late in March 2026 after exercising fully vested options. On March 25, 2026, Kaplan sold 14,295 shares of common stock at a weighted average price of $36.9714 per share, for a total of $528,506. The executed price range that day was $36.95 to $37.11. Following that sale, Kaplan continued to hold 28,231 shares of Tyra Biosciences directly.
The activity continued the following day. On March 26, 2026, Kaplan sold an additional 53,172 shares at a weighted average price of $37.7483 per share, generating proceeds of $2,007,152. The prices realized on March 26 ranged from $37.25 to $38.125.
Both blocks sold in late March were preceded by option exercises. On the same dates Kaplan exercised options to acquire the 14,295 and 53,172 shares of Tyra Biosciences common stock at an exercise price of $2.25 per share, for an aggregate exercise cost of $151,800. The options were described as fully vested and exercisable, which produced a material gain derived from the low exercise price relative to contemporaneous market levels.
Those insider transactions unfolded while the stock traded near its 52-week high of $39.15, following a reported 294% increase over the past year. At the time of the reporting included in this piece, the stock was quoted at $36.29 and the company had a market capitalization of $2.05 billion. Separately, InvestingPro analysis cited in the company commentary indicated the shares appeared overvalued at current levels, though sell-side coverage remained largely supportive.
Market interest in Tyra extended beyond insider activity. The company completed a $126 million stock sale in a block transaction, issuing 4,000,000 shares at $31.50 per share to a large investment management firm, with the proceeds earmarked to support ongoing development efforts.
Analyst posture has been constructive around Tyra's clinical program and pipeline strategy. Piper Sandler reiterated an Overweight rating with a $56.00 price target after receiving positive feedback on the company’s oral FGFR3-selective inhibitor in bladder cancer. H.C. Wainwright reaffirmed a Buy rating with a $45.00 price target, underscoring Tyra’s focus on advancing dabogratinib across indications. William Blair initiated coverage with an Outperform rating and a fair value estimate of $59.62, highlighting dabogratinib’s potential as a first-in-class selective FGFR3 inhibitor. Collectively these research notes contributed to what was described as a Strong Buy consensus, with price targets spanning $37 to $59.62.
These transactions and financing moves present a snapshot of capital activity around Tyra Biosciences as the company pushes forward with development work on dabogratinib and related programs.